Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HealthEquityFRA:2HE +2.38%93 3-Year ROIIC % is 116.81 as of Jan. 2026, which is 383% above its 10-year median of 24.19. GuruFocus rates FRA:2HE with a GF Score™ of 93/100 and a GF Value™ of €91.23. The stock has 3 warning signs investors should review. Among 618 Healthcare Providers & Services companies, HealthEquity ranks better than 89.64% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
HealthEquity's 3-Year ROIIC % for the quarter that ended in Jan. 2026 was 116.81%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for HealthEquity's 3-Year ROIIC % or its related term are showing as below:
FRA:2HE's 3-Year ROIIC % is ranked better than 89.64% of 618
companies
in the Healthcare Providers & Services industry
Industry Median: 3.37
vs FRA:2HE: 116.81
HealthEquity (FRA:2HE) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
HealthEquity 3-Year ROIIC % Related Terms
HealthEquity 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for HealthEquity's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2HE vs HNGE, TEM, TXG: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, HealthEquity's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthEquity 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthEquity's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where HealthEquity's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
HealthEquity (FRA:2HE) has a 3-Year ROIIC % of 116.81 as of Jan. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on HealthEquity and its competitors. This is 383% above median its historical median of 24.19. According to the industry distribution chart, HealthEquity ranks #64 out of 618 companies in the Healthcare Providers & Services industry, placing it in the top 10.4%.
Is HealthEquity's 3-Year ROIIC % too high?
HealthEquity's current 3-Year ROIIC % of 116.81 is 383% above median its 10-year median of 24.19. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.37. HealthEquity's value of 116.81 is 3366.2% above this industry median. Based on the distribution chart, HealthEquity ranks #64 out of 618 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, HealthEquity has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's 3-Year ROIIC % compare to HNGE and TEM?
According to the Healthcare Providers & Services industry distribution chart, HealthEquity ranks #64 out of 618 companies for 3-Year ROIIC %. This places HealthEquity in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.37. HealthEquity's value of 116.81 is 3366.2% above this benchmark. While the company's 10-year median is 24.19 vs. the industry median of 3.37, HealthEquity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.37, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HealthEquity's current 3-Year ROIIC % of 116.81 is 3366.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on HealthEquity and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HealthEquity's current 3-Year ROIIC % is 116.81, which is 383% above median its own 10-year median of 24.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
HealthEquity (FRA:2HE) has a current 3-Year ROIIC % of 116.81. The stock's GF Value™ is €91.23, compared to a current price of €86.00 — trading 5.7% below its estimated fair value. The current 3-Year ROIIC % is 116.81, which is 383% above median its 10-year median of 24.19 and 3366.2% above the Healthcare Providers & Services industry median of 3.37. HealthEquity's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current 3-Year ROIIC % is 116.81 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthEquity (FRA:2HE) Overvalued in 2026?
Based on GuruFocus' analysis, HealthEquity stock appears to be undervalued.
The current stock price of €86.00 is trading 5.7% below its estimated GF Value™ of €91.23.
Key valuation signals for FRA:2HE:
3-Year ROIIC %: 116.81 (383% above median its 10-year median of 24.19)
GF Value™: €91.23 vs. price of €86.00 (5.7% below fair value)
Industry Position: 3366.2% above the Healthcare Providers & Services median (#64 of 618)
No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
93GF Score
Get the complete analysis for FRA:2HE
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2HE has been successfully added to your 
